Get the Stockscreener App
0.586
6.33%
-0.0396
Dermata Therapeutics Inc stock is traded at $0.586, with a volume of 103.13K.
It is down -6.33% in the last 24 hours and down -21.24% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$0.6256
Open:
$0.627
24h Volume:
103.13K
Relative Volume:
0.08
Market Cap:
$4.78M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.0274
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-15.57%
1M Performance:
-21.24%
6M Performance:
-56.79%
1Y Performance:
-77.72%
1-Day Range:
$0.5739
$0.6317
1-Week Range:
$0.5739
$0.6849
52-Week Range:
$0.5739
$5.00
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.586 | 4.78M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Primary Axillary Hyperhidrosis Pipeline 2025: Groundbreaking - openPR.com
Dermata stock hits 52-week low at $0.69 amid market challenges - Investing.com India
Dermata stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 57.0% in May - Defense World
Dermata Therapeutics (NASDAQ:DRMA) Stock Price Down 2% – Time to Sell? - Defense World
Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $3.00 - Defense World
Dermata gears up for phase 3 trial of XYNGARI By Investing.com - Investing.com Nigeria
Maxim Group cuts Dermata Therapeutics target to $3 By Investing.com - Investing.com Nigeria
Dermata gears up for phase 3 trial of XYNGARI - Investing.com
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial - TipRanks
Dermata Therapeutics IncPotential NDA Filing For Xyngari In H1 2028SEC Filing - marketscreener.com
Maxim Group cuts Dermata Therapeutics target to $3 - Investing.com
Dermata Therapeutics (DRMA) Price Target Cut Amid Capital Raise - GuruFocus
Dermata Faces Nasdaq Delisting Risk Over Bid Price - TipRanks
Dermata (DRMA) Achieves Positive Phase 3 Trial Results for Acne Treatment | DRMA Stock News - GuruFocus
DRMA: Substantial Cash Increase Enhances Financial Stability | DRMA Stock News - GuruFocus
Dermata Reports Positive Phase 3 Trial Results - TipRanks
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire
Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView
Revolutionary Once-Weekly Natural Acne Treatment Achieves Breakthrough in Phase 3 Trial Results - Stock Titan
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - ACCESS Newswire
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire
DRMAWDermata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia
Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa
Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus
Dermata reports early success in acne treatment with XYNGARI - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World
Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada
Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Dermata Therapeutics stock hits 52-week low at $1 - Investing.com
Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus
Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):